ESMO 2022: Triplet Therapy Improves Outcomes in Metastatic Renal Cell Carcinoma
Addition of cabozantinib to ipilimumab plus nivolumab led to improvement in progression-free survival
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Renal Cell Carcinoma Center of Excellence
Visit our Renal Cell Carcinoma Center of Excellence for additional, in-depth coverage.